clifutinib

Clifutinib is an orally bioavailable, selective small molecule inhibitor of Fms-like tyrosine kinase 3 (FLT3), also known as CD135, STK1, or FLK2. It is being developed primarily for the treatment of acute myeloid leukemia (AML), particularly in patients with FLT3 mutations. By inhibiting FLT3 activity, clifutinib suppresses the proliferation and survival of leukemic cells, thereby slowing disease progression. The drug has demonstrated significant anti-leukemic activity and an acceptable safety profile in clinical trials for relapsed/refractory AML with FLT3 mutations[1][2][4][5]. Clifutinib was originally developed by HEC Pharm and further developed by Sunshine Lake Pharma[3][5].

Other names

clifutinib besylate